HomeCompareBNOEF vs SCHD

BNOEF vs SCHD: Dividend Comparison 2026

BNOEF yields 33333.33% · SCHD yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNOEF wins by $8.428195308647591e+21M in total portfolio value
10 years
BNOEF
BNOEF
● Live price
33333.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.428195308647591e+21M
Annual income
$8,378,748,509,141,157,000,000,000,000.00
Full BNOEF calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.46%
Share price
$30.48
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$425.95
Full SCHD calculator →

Portfolio growth — BNOEF vs SCHD

📍 BNOEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNOEFSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNOEF + SCHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNOEF pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNOEF
Annual income on $10K today (after 15% tax)
$2,833,333.33/yr
After 10yr DRIP, annual income (after tax)
$7,121,936,232,769,983,000,000,000,000.00/yr
SCHD
Annual income on $10K today (after 15% tax)
$294.40/yr
After 10yr DRIP, annual income (after tax)
$362.06/yr
At 15% tax rate, BNOEF beats the other by $7,121,936,232,769,983,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNOEF + SCHD for your $10,000?

BNOEF: 50%SCHD: 50%
100% SCHD50/50100% BNOEF
Portfolio after 10yr
$4.2140976543237957e+21M
Annual income
$4,189,374,254,570,578,700,000,000,000.00/yr
Blended yield
99.41%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNOEF buys
0
SCHD buys
0
No recent congressional trades found for BNOEF or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNOEFSCHD
Forward yield33333.33%3.46%
Annual dividend / share$2.00$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.428195308647591e+21M$29.0K
Annual income after 10y$8,378,748,509,141,157,000,000,000,000.00$425.95
Total dividends collected$8.424943808765552e+21M$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BNOEF vs SCHD ($10,000, DRIP)

YearBNOEF PortfolioBNOEF Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$3,344,033$3,333,333.33$11,226$346.36+$3.33MBNOEF
2$1,045,333,048$1,041,754,932.50$12,572$357.38+$1045.32MBNOEF
3$305,463,295,767$304,344,789,404.97$14,046$367.84+$305463.28MBNOEF
4$83,443,192,327,233$83,116,346,600,762.75$15,660$377.73+$83443192.31MBNOEF
5$21,308,754,850,592,396$21,219,470,634,802,260.00$17,425$387.07+$21308754850.57MBNOEF
6$5,087,082,937,849,453,000$5,064,282,570,159,319,000.00$19,354$395.86+$5087082937849.43MBNOEF
7$1,135,355,897,925,379,400,000$1,129,912,719,181,880,500,000.00$21,461$404.13+$1135355897925379.50MBNOEF
8$236,895,694,937,506,160,000,000$235,680,864,126,726,020,000,000.00$23,762$411.89+$236895694937506176.00MBNOEF
9$46,211,962,155,546,610,000,000,000$45,958,483,761,963,480,000,000,000.00$26,272$419.15+$46211962155546607616.00MBNOEF
10$8,428,195,308,647,591,000,000,000,000$8,378,748,509,141,157,000,000,000,000.00$29,010$425.95+$8.428195308647591e+21MBNOEF

BNOEF vs SCHD: Complete Analysis 2026

BNOEFStock

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Full BNOEF Calculator →

SCHDETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this BNOEF vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNOEF vs JEPIBNOEF vs OBNOEF vs KOBNOEF vs MAINBNOEF vs VYMBNOEF vs DGROBNOEF vs VIGBNOEF vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.